LIVE

IRMD

IRadimed Corporation

IRMD

NASDAQ·Healthcare·Medical - Devices·Mkt cap $1.3B

$100.97

▲ +2.99%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$55.11 - $107.90

P/E

54.88

Fwd P/E

47.63

Beta

0.92

Div Yield

1.26%

Avg Vol

130.7K

Shares Out

12.8M

Mkt Cap

$1.3B

Price action

Price chart

Up 59.3% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary MRI-compatible technology with limited direct competition in specialized market
  • Established relationships with hospitals and imaging centers requiring regulatory compliance solutions
  • Recurring revenue model through disposable IV tubing sets and accessories
  • Regulatory certifications and clearances creating barriers to entry for competitors
▼

Bear Case

2 risks

  • Average volatility.
  • High premium - requires strong execution

Growth

Stable outlook

Increasing global MRI procedure volumes and hospital adoption rates

Value

High premium - requires strong execution

Momentum

Stable

+1.9% over 3m

Quality

Excellent

Excellent business quality

Dividend

Modest

1.26% yield

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 24, 2026

“
Q2 26 RECAP

MAY 1, 2026

Reported EPS of $0.49 vs $0.46 consensus (+6.5% surprise). Revenue of $22.0M vs $21.3M expected (+3.1%). Beat on both top and bottom lines.

EPS beat +6.5%
Rev beat +3.1%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+6.5%

Next: Apr 24, 2026

Revenue trend · last 8Q

—

—

+11%

+11%

+14%

+16%

+17%

+13%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$17.9M

$18.3M

$19.4M

$19.5M

$20.4M

$21.2M

$22.7M

$22.0M

Margins · last 8Q

Gross

—

Operating

—

Profit

26.5%

View full earnings history →

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

No analyst coverage on file for this stock yet.

View full analyst page →

vs Industry

How IRMD stacks vs Medical - Devices

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.